Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 5, 2026, 6:57 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 64 matching trials from the live ClinicalTrials.gov search.
Filters: Condition: Brimonidine Tartrate Clear all
Completed Phase 4 Interventional Results available

24-hour IOP-lowering Effect of Brimonidine 0.1%

NCT00457795
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
brimonidine 0.1% (Alphagan® P)
Drug
Lead sponsor
Allergan
Industry
Eligibility
40 Years to 80 Years
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2009
U.S. locations
1
States / cities
San Diego, California
Source: ClinicalTrials.gov public record
Updated Nov 24, 2011 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Results available

Pharmacokinetics of the Brimonidine Tartrate Posterior Segment Delivery System in Patients Undergoing Pars Plana Vitrectomy

NCT01229410
View directory record Official record
Conditions
Vitrectomy
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
24 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Salt Lake City, Utah
Source: ClinicalTrials.gov public record
Updated Aug 5, 2013 · Synced Oct 5, 2026, 6:57 AM EDT
Terminated Phase 2 Interventional Results available

A Safety and Efficacy Study of Brimonidine Intravitreal Implant in Geographic Atrophy Secondary to Age-related Macular Degeneration

NCT02087085
View directory record Official record
Conditions
Geographic Atrophy, Macular Degeneration
Interventions
400 µg Brimonidine Implant, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
55 Years and older
Enrollment
310 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
23
States / cities
Phoenix, Arizona • La Jolla, California • Mountain View, California + 19 more
Source: ClinicalTrials.gov public record
Updated Apr 23, 2019 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Safety Extension Study to Evaluate the Biodegradation of the Brimonidine Tartrate Posterior Segment Drug Delivery System

NCT01080209
View directory record Official record
Conditions
Patients Who Participated in an Intravitreal Brimo PS DDS® Study
Interventions
Brimo PS DDS®, Sham
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
215 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2014
U.S. locations
1
States / cities
Artesia, California
Source: ClinicalTrials.gov public record
Updated Feb 20, 2015 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Brimonidine/Timolol Fixed Combination in Patients With Glaucoma or Ocular Hypertension

NCT00652106
View directory record Official record
Conditions
Glaucoma, Ocular Hypertension
Interventions
0.2% brimonidine/0.5% timolol fixed combination ophthalmic solution, Concurrent brimonidine 0.2% and Timolol 0.5% ophthalmic solution, Brimonidine 0.2% ophthalmic solution
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
432 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
1
States / cities
El Paso, Texas
Source: ClinicalTrials.gov public record
Updated Apr 3, 2008 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Results available

Safety and Efficacy of Brimonidine Intravitreal Implant in Patients With Geographic Atrophy Due to Age-related Macular Degeneration (AMD)

NCT00658619
View directory record Official record
Conditions
Macular Degeneration
Interventions
400 µg Brimonidine Tartrate Implant, 200 µg Brimonidine Tartrate Implant, Sham (no implant)
Drug · Other
Lead sponsor
Allergan
Industry
Eligibility
50 Years and older
Enrollment
119 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2011
U.S. locations
1
States / cities
Abilene, Texas
Source: ClinicalTrials.gov public record
Updated Aug 21, 2018 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Participants With Ocular Redness

NCT01959230
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013
U.S. locations
1
States / cities
Memphis, Tennessee
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Safety of Brimonidine Tartrate Ophthalmic Solution in a Population of Pediatric, Adult, and Geriatric Participants

NCT01959243
View directory record Official record
Conditions
Hyperemia
Interventions
Brimonidine Tartrate, Vehicle, Sodium Fluorescein, Fluorescein Sodium and Benoximate Hydrocholoride Ophthalmic Solution USP
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
507 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2014
U.S. locations
4
States / cities
Phoenix, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 1 more
Source: ClinicalTrials.gov public record
Updated Oct 23, 2019 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Early Phase 1 Interventional Results available

Aqueous Humor Dynamics and Brimonidine

NCT01144494
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Brimonidine, Artificial tears
Drug
Lead sponsor
University of Nebraska
Other
Eligibility
19 Years and older
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2011
U.S. locations
1
States / cities
Omaha, Nebraska
Source: ClinicalTrials.gov public record
Updated Nov 28, 2023 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Effectiveness of Aceclidine (LNZ101) and Aceclidine + Brimonidine (LNZ100) in the Treatment of Presbyopia

NCT05431543
View directory record Official record
Conditions
Presbyopia, Refractive Errors, Eye Diseases
Interventions
Aceclidine+Brimonidine combination ophthalmic solution, Aceclidine ophthalmic solution, Vehicle proprietary ophthalmic solution
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
45 Years to 75 Years
Enrollment
59 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022
U.S. locations
5
States / cities
Chandler, Arizona • Glendale, California • Andover, Massachusetts + 2 more
Source: ClinicalTrials.gov public record
Updated Sep 5, 2024 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

Plasma Pharmacokinetics and Safety of LNZ101 and LNZ100 Ophthalmic Solutions in Healthy Adult Subjects With Presbyopia

NCT05936489
View directory record Official record
Conditions
Eye Diseases, Presbyopia, Refractive Errors, Brimonidine Tartrate, Aceclidine, Ophthalmic Solutions
Interventions
Aceclidine + Brimonidine, Aceclidine
Drug
Lead sponsor
LENZ Therapeutics, Inc
Other
Eligibility
45 Years to 75 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional

Study of Medical Treatment of Low-Pressure (Normal Tension) Glaucoma

NCT00317577
View directory record Official record
Conditions
Glaucoma, Open Angle
Interventions
brimonidine, timolol
Drug
Lead sponsor
Chicago Center for Vision Research
Other
Eligibility
30 Years and older
Enrollment
160 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
1998 – 2004
U.S. locations
12
States / cities
Little Rock, Arkansas • Gainesville, Florida • Palm Beach Gardens, Florida + 7 more
Source: ClinicalTrials.gov public record
Updated Apr 25, 2006 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 2 Interventional Accepts healthy volunteers

Study Evaluating the Safety and Efficacy of Brimonidine Tartrate Ophthalmic Solution in Adult and Geriatric Subjects

NCT01675609
View directory record Official record
Conditions
Ocular Redness
Interventions
Placebo, Brimonidine tartrate 0.025%
Drug
Lead sponsor
Eye Therapies, LLC
Industry
Eligibility
40 Years and older
Enrollment
57 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
Started 2012
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jul 31, 2014 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Study of Brimonidine Tartrate Nanoemulsion Eye Drop Solution in the Treatment of Dry Eye Disease (DED)

NCT03785340
View directory record Official record
Conditions
Dry Eye
Interventions
Brimonidine Tartrate, Placebos
Drug
Lead sponsor
Ocugen
Industry
Eligibility
18 Years and older
Enrollment
252 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2019
U.S. locations
16
States / cities
Newport Beach, California • Rancho Cordova, California • Pompano Beach, Florida + 11 more
Source: ClinicalTrials.gov public record
Updated Jul 18, 2022 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Results available

Randomized, Double-blind, Multiple-site, Placebo-controlled, Parallel-design Study in Patients With Moderate to Severe Facial Erythema Associated With Rosacea

NCT02289352
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine, placebo
Drug
Lead sponsor
Actavis Inc.
Industry
Eligibility
18 Years and older
Enrollment
462 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014
U.S. locations
16
States / cities
Hot Springs, Arkansas • Long Beach, California • Miami, Florida + 12 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2020 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional

A Study Comparing the Efficacy and Safety of Brimonidine Tartrate Ophthalmic Solution 0.025% With Sodium Hyaluronate Relative to Lumify in Adult Subjects With Ocular Redness

NCT06803654
View directory record Official record
Conditions
Ocular Redness
Interventions
BTOS-HA, Lumify®
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
578 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025
U.S. locations
11
States / cities
Glendale, California • Newport Beach, California • Northbrook, Illinois + 8 more
Source: ClinicalTrials.gov public record
Updated May 28, 2026 · Synced Oct 5, 2026, 6:57 AM EDT
Not yet recruiting Phase 4 Interventional

The Effect of Lumify™ on Ocular Redness, Intraocular Pressure, and Eyelid Position in Glaucoma Patients

NCT04007276
View directory record Official record
Conditions
Glaucoma, Glaucoma, Open-Angle, Glaucoma; Drugs, Droopy Eyelid, Ptosis, Glaucoma, Primary Open Angle
Interventions
brimonidine tartrate ophthalmic solution 0.025%, sterile balanced saline solution
Drug · Other
Lead sponsor
Tulane University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2036
U.S. locations
1
States / cities
New Orleans, Louisiana
Source: ClinicalTrials.gov public record
Updated Oct 1, 2025 · Synced Oct 5, 2026, 6:57 AM EDT
Withdrawn Phase 4 Interventional Accepts healthy volunteers

Brimonidine for Intraoperative Hemostasis

NCT05480098
View directory record Official record
Conditions
Dermatochalasis of Eyelid, Ptosis, Eyelid, Ectropion, Entropion
Interventions
Brimonidine Topical
Drug
Lead sponsor
University of Louisville
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2024
U.S. locations
1
States / cities
Louisville, Kentucky
Source: ClinicalTrials.gov public record
Updated Jan 15, 2025 · Synced Oct 5, 2026, 6:57 AM EDT
Completed No phase listed Observational Accepts healthy volunteers

Effect of Brimonidine Tartrate Ophthalmic Solution 0.15% on Pupil Diameter in Normal Eyes

NCT00413751
View directory record Official record
Conditions
Healthy
Interventions
Brimonidine tartrate ophthalmic solution 0.15% (Alphagan P)
Drug
Lead sponsor
Walter Reed Army Medical Center
Federal
Eligibility
18 Years to 50 Years
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
U.S. locations
1
States / cities
Washington D.C., District of Columbia
Source: ClinicalTrials.gov public record
Updated Dec 20, 2006 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 3 Interventional Accepts healthy volunteers Results available

Evaluation of the Safety and Pharmacokinetics of Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Combination Ophthalmic Solution

NCT05815758
View directory record Official record
Conditions
Allergic Conjunctivitis
Interventions
Brimonidine Tartrate 0.025%/Ketotifen Fumarate 0.035% Ophthalmic Solution (Combo), Vehicle of brimonidine tartrate 0.025%/ketotifen fumarate 0.035% ophthalmic solution
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
5 Years and older
Enrollment
512 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
7
States / cities
Chandler, Arizona • Havre de Grace, Maryland • Andover, Massachusetts + 4 more
Source: ClinicalTrials.gov public record
Updated Jul 10, 2025 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 4 Interventional Results available

MirvasO Soolantra Association In the Treatment of Moderate to Severe rosaCea.

NCT02616250
View directory record Official record
Conditions
Rosacea
Interventions
Brimonidine 0.33% gel (Br), CD07805/47 (Br) placebo gel, Ivermectin 1% cream (IVM), CD5024 (IVM) placebo cream
Drug · Other
Lead sponsor
Galderma R&D
Industry
Eligibility
18 Years and older
Enrollment
190 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
7
States / cities
Fort Smith, Arkansas • Rogers, Arkansas • Sacramento, California + 4 more
Source: ClinicalTrials.gov public record
Updated Feb 18, 2021 · Synced Oct 5, 2026, 6:57 AM EDT
Terminated Phase 4 Interventional Results available

Safety and Efficacy of SIMBRINZA® BID as an Adjunctive to DUOTRAV®

NCT02730871
View directory record Official record
Conditions
Open-angle Glaucoma, Ocular Hypertension
Interventions
Brinzolamide 1%/brimonidine tartrate 0.2% ophthalmic suspension, Brinzolamide/brimonidine vehicle, Travoprost 0.004%/timolol 0.5% solution
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2018
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated May 29, 2019 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

The Effect of Brimonidine on Intraocular Pressure When Dilating Routine Patients

NCT03139708
View directory record Official record
Conditions
Intraocular Pressure
Interventions
Alphagan, Phenylephrine, Tropicamide
Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years to 50 Years
Enrollment
5 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2016 – 2017
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Aug 9, 2018 · Synced Oct 5, 2026, 6:57 AM EDT
Completed Not applicable Interventional Results available

Effect of Alphagan on Retinal Blood Flow Autoregulation and Motion Detection in Patients With Normal Pressure Glaucoma

NCT01105065
View directory record Official record
Conditions
Glaucoma
Interventions
brimonidine 0.15%
Drug
Lead sponsor
Massachusetts Eye and Ear Infirmary
Other
Eligibility
35 Years to 80 Years
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Apr 4, 2017 · Synced Oct 5, 2026, 6:57 AM EDT